Agenus Q3 2026 net income drops 96% year over year to $2.8 million

By Public Technologies
  • Agenus’ third-quarter 2026 net income fell 96% year over year to $2.8 million; revenue rose to $31.5 million.
  • Cash, cash equivalents and short-term investments increased from the previous quarter to $86.9 million at September 30, 2026.
  • Armenia granted the first worldwide marketing authorizations for botensilimab and balstilimab, each for use in combination with the other.
  • The Phase 3 ROBBIN trial remains on track for first patient enrollment in Q1 2027.
  • July financing proceeds are expected to support operations through Q3 2027, extending through year-end 2031 if milestone-aligned warrants are fully exercised.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050730BIZWIRE_USPR_____20261105_BW453521) on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.